Disputations in May 2013
Ola Myklebost has been the main supervisor for Heidi Maria Namløs and Hege Oma Ohnstad, both defending their theses in May 2013.
Helse Sørøst Månedens forsker januar 2013
Månedens forsker januar 2013:
Ola Myklebost jakter på formelen for persontilpasset kreftbehandling. Først må han knekke kreftgenomet.
Av Ram Gupta, Oslo universitetssykehus , Helse Sør-Øst RHF
Ola Myklebost er månedens forsker i Helse Sør-Øst.
Ved hjelp av avansert genteknologi presser de på for å knekke koden til kreftgenomet, Ola Myklebost og hans forskerkolleger.
Når koden gir etter kan de finne formelen for persontilpasset kreftbehandling.
Basert på en analyse av mutasjonsprofilen til den enkelte kreftsvulsten ønsker de å fastsette en perfekt miks av individuelt tilpassede medisiner. Pasienten slipper å gå på flere kreftmedisiner enn nødvendig.
Kreftbehandlingen kan bli billigere for samfunnet og mer skånsom for pasienten.
Substantial support from "The Programme for Publicly-initiated Clinical Cancer Studies" to projects led by Mælandsmo, Loge and Myklebost
The Programme for Publicly-initiated Clinical Cancer Studies provides support to research projects that will increase understanding and thereby enhance the basis for effective decision-making within cancer treatment and care. The Research Council collaborates with the Norwegian Council for Quality Improvement and Priority Setting in Health Care on the selection of proposed topics for calls for proposals.
Comment on Myklebosts role in initiation of the Nordic microarray network
See the BioChipNet page
Head of the RR/UiO Microarray Core Faclity
More about the DNR Microarray Project
The new RR/UiO Facility offers extended services using also commercial array technology.
See the RR/UiO Core Facility web page
The Microarry Core Facility at the RR HF - led by Ola Myklebost from the Department of Tumor Biology - has been allotted a 10 Mkr grant to continue as the Oslo node of the national FUGE Microarray Platform.
Siv. ing. Stine Henrichson Kresse defended her PhD thesis, entitled "Chromosomal aberrations in human sarcomas identified using genomic microarrays" on Tuesday May 20th. Her trial lecture - on the topic “Microarrays: identification of gene signatures and their application in clinical practice. An update" was held the day before.
Characterization of LSAMP, a novel candidate tumor suppressor gene in osteosarcomas.
Veileder Ola Myklebost, Leonardo Meza-Zepeda, Stine H. Kresse
Sensor: Heidi Rudi, UMB, Uwe Klein, IMBV
Eivind Valen Egeland
Osteogenic differentiation of mesenchymal stem cells: Identification of potential regulators
Veileder Ola Myklebost, Leonardo Meza-Zapeda, Anne Mari Håkelien
Sensorer: Heidi Rudi, UMB, Paul E. Grini, IMBV
As part of the EuroBoNet Network of Excellence on Bone Tumours, Leonardo and colleagues within the NoE have carefully evaluated the available technologies for copy number profiling on this type of tumours, a work which was recently published in BMC Research Notes. This acught the interest of the Genomeweb online publication, and led to an interview about the work.
Combination of stem cell model system from Center group with innovative use of microfluidics to control in vitro stem cell niches
A news article is about the following paper: Extensive adipogenic and osteogenic differentiation of patterned human mesenchymal stem cells in a microfluidic device, Ellen Tenstad, Anna Tourovskaia, Albert Folch, Ola Myklebost and Edith Rian, Lab Chip, 2010
The Microarray Core Facility celebrates its 10 year anniversary this year. On this occasion, a special research seminar was held on Thursday February 26th, entitled "10 Years Anniversary of the Rikshospitalet/University of Oslo - Microarray Core Facility". The seminar took place in the Auditorium at The Norwegian Radium Hospital. Lectures were held by Ola Myklebost, Leonardo Meza-Zepeda, Joakim Lundeberg and Michael R. Stratton.
The lectures are now available on Web TV.
The BIOTEK2021 programme is the Research Council of Norway’s most comprehensive research initiative in the field of biotechnology and will run from 2012 through 2021. The programme board has now granted support to five large projects, covering all relevant thematic fields, and are expected to boost the development of commercial biotechnology in Norway.
News article in Nature on Norwegian plans for using tumour-sequencing techniques to help guide cancer care
The February 2nd edition of Nature brings a feature article in their news section about Norway's current plans to use "next-generation" DNA sequencers to trawl for mutations in tumours that might reveal which cancer treatments would be most effective.
Member of the FUGE board at the University of Oslo
EMBIO, also functions as institutional FUGE board.
In a Commentary on "The future of gene therapy" in Nature (Cavazzana-Calvo et al. Nature 427, 779-781; 2004), a large map illustrated the number of gene therapy trials in different countries, indicating that no trials have been performed in Norway. Because Norway has the reputation of a prohibitive country when it comes to biotechnology, this incorrect impression can have serious consequences for the interest of pharmaceuticaal companies. Myklebost tries to set the record straight. Seven gene therapy trials have been performed in Norway, of which six at the Norwegian Radium Hospital.
Nature May 13th 2004
Listen to the lecture (in Norwegian) by clicking here.
Read article about "Stamcellenes mørke side" from the P2 academy web page here (in Norwegian).
International Sarcoma Symposium
Supported by the Liddy Shriver Sarcoma Initiative, we have established an international liposarcoma research consortium, consisting of two American (Maki, Barretina), one Australian (Thomas), and one Norwegian group (Myklebost/Meza-Zepeda). This web site is set up to further this collaboration and invite other groups to provide their links, as well as to advertise what we are doing in the hope to extend our collaborations further.
A figure from the article entitled "Extensive adipogenic and osteogenic differentiation of patterned human mesenchymal stem cells in a microfluidic device" was chosen as the cover illustration for a recent issue of the prestigious journal "Lab on a chip" (impact factor 6.5). The paper has been highly accessed, and is currently among the ten most accessed "Lab on a Chip" articles on the web.
The official opening of the Norwegian Center for Stem Cell Research took place on Friday, November 27, 2009 at 1300. The opening started with a short ceremony near the Center's facilities at Domus Medica. Statements were made by the following officials and representatives: Anne-Grete Strøm-Erichsen, Annetine Staff, Ole Petter Ottersen, Hilde Jerkø, Steinar Funderud, Erlend Smeland and Joel Glover.